Immunogenicity of native or pegylated E. coli and Erwinia asparaginases assessed by ELISA and surface plasmon resonance (SPR-Biacore) assays of IgG antibodies (Ab) in sera from patients with acute lymphoblastic leukemia (ALL)

Anticancer Research

Volumn 29, Issue 1, 2009, Pages 299-302

  Avramis, Vassilios I ^a,d   Avramis, Earl V ^b   Hunter, William ^c   Long, Melissa C ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Biacore Inc   (United States)

^d Division of Hematology Oncology   (United States)

Author keywords

ALL; Antibody; Asparaginases; IgG immunoglobulin; Immunogenicity

Indexed keywords

ASPARAGINASE; ASPARAGINASE MACROGOL; BACTERIAL PROTEIN; IMMUNOGLOBULIN G ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERWINIA; ESCHERICHIA COLI; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOGENICITY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SURFACE PLASMON RESONANCE;

ADULT; ASPARAGINASE; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; ERWINIA; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN G; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN ARRAY ANALYSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURFACE PLASMON RESONANCE;

EID: 61449179384     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Wadhwa W, Bird C, Dilger P, Gaines-Das R and Thorpe R: Strategies for detection, measurement, and characterization of unwanted antibodies induced by therapeutic biologicals. J Immunol Methods 278: 1-17, 2003.
2. Avramis VI and Panosyan EH: Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 44: 367-393, 2005.
3. Panosyan EH, Seibel NL, Martin-Aragon S, Gaynon PS, Avramis IA, Sather H, Franklin J, Nachman J, Ettinger LJ, La M, Steinherz P, Cohen LJ, Siegel SE and Avramis VI: Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 26: 217-226, 2004.
4. Gaynon PS: Childhood acute lymphoblastic leukaemia and relapse. Br J Haematol 131: 579-587, 2005.
5. Kishi S, Evans WE and Relling MV: Pharmacokinetic, pharmacodynamic, and pharmacogenetic considerations. In: Childhood Leukemias, 2nd Edition, Ching-Hon Pui (ed.). Cambridge University Press, pp. 391-413, 2006.
6. Woo MH, Hak LJ, Storm MC, Evans WE, Sandlund JT, Rivera GK, Wang B, Pui CH and Relling MV: Anti-asparaginase antibodies following E. coli asparaginase therapy in pediatric acute lymphoblastic leukemia. Leukemia 12: 1527-1533, 1998.
7. Woo MH, Hak LJ, Storm MC, Sandlund JT, Ribeiro RC, Rivera GK, Rubnitz JE, Harrison PL, Wang B, Evans WE, Pui CH and Relling MV: Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 18: 1525-1532, 2000.
8. Wang B, Relling MV, Storm MC, Woo MH, Ribeiro R, Pui CH and Hak LJ: Evaluation of immunologic cross-reaction of anti-asparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 17: 1583-1588, 2003.
9. Avramis VI, Sencer S, Periclou AP, Sather H, Bostrom BC, Cohen LJ, Ettinger AG, Ettinger LJ, Franklin J, Gaynon PS, Hilden JM, Lange B, Majlessipour F, Mathew P, Needle M, Neglia J, Reaman G, Holcenberg JS and Stork L: A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 99: 1986-1994, 2002.
10. Avramis VI, Martin-Aragon S, Avramis EV and Asselin BL: Pharmacoanalytical assays of Erwinia asparaginase (Erwinase) and pharmacokinetic results in high-risk acute lymphoblastic leukemia (HR ALL) patients: simulations of Erwinase population PK-PD models. Anticancer Res 27: 2561-2572, 2007.
11. Tiwari PN, Zielinski M, Quinn JJ, Siegel SE, Gaynon PS, Wakamatsu P, Seibel NL and Avramis VI: Assessment of anti-asparaginase (ASNase) antibodies (Ab) and ASNase activity after suspected clinical allergy. Blood 108: 532a, (Abstr # 1878), 2006.
12. Lofgren JA, Dhandapani S, Pennucci JJ, Abbott CM, Mytych DT, Kaliyaperumal A, Swanson SJ and Mullenix MC: Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol 178: 7467-7472, 2007.
13. Swanson SJ, Mytych D and Ferbas J: Use of biosensors to monitor the immune response. Dev Biol (Basel) 109: 71-78, 2002.
14. Jacobsen CG, Bodtger U, Kristensen P, Poulsen LK and Roggen EL: Isolation of high-affinity human IgE and IgG antibodies recognizing Bet v1 and Humicola languinosa lipase from combinatorial phase libraries. Mol Immunol 41: 941-953, 2004.
15. Kamal N, Chowdhury S, Madan T, Sharma D, Atteyi M, Hag W, Katti SB, Kumar A and Sarma PU: Tryptophasn residue is essential for immunoreactivity of a diagnostically relevant peptide epitope of A. Fumigatus. Mol Cell Biochem 275: 223-232, 2005.